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Abstract 1 
Background.  Glomerular endocapillary inflammation may proceed to crescent formation 2 
and exuded protein leakage, which may induce tubulointerstitial injury (TII) in 3 
glomerulonephritis. Therefore we naturally think the grade of crescentic formation should 4 
relate with the severity of TII. However, it is well known that the severity of TII was not 5 
correlated with that of glomerulonephritis in anti-neutrophil cytoplasmic antibody 6 
(ANCA)-associated crescentic glomerulonephritis (ANCAGN). Activated neutrophils by 7 
ANCA have been shown to release neutrophil extracellular traps (NETs), and which plays a 8 
role for a trigger of sterile inflammation using the Nod-like receptor family pyrin domain–9 
containing-3 (NLRP3) inflammasome. The aim of this study was to indicate the sterile 10 
inflammation is a distinct mechanism of TII in ANCAGN.    11 
Methods. Twenty-two myeloperoxidase-ANCA-positive ANCAGN patients were enrolled, 12 
and their kidney biopsy specimens were evaluated with regard to glomerular injury (GI) and 13 
TII. For a disease control group 25 patients with crescentic IgA nephropathy were also 14 
enrolled. GI was represented by cellular crescent formation rate (cCFR), and TII was 15 
exhibited by cellular TII (cTII), which is the average number of infiltrating cells. The 16 
expressions of calprotectin in the biopsy specimens were immunohistologically evaluated. 17 
The mRNA expressions of inflammasome related molecules were examined.      18 
Results. The correlation between the values of cCFR and cTII was recognized in IgAN, but 19 
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not in ANCAGN. However, the positivity of calprotectin was correlated with the value of 1 
cTII in ANCAGN. The mRNA expression of Interleukin-1 was significantly correlated 2 
with the value of cTII in ANCAGN. The Toll-like receptor 4 (TLR4) and NLRP3 also 3 
correlated in ANCAGN. Immunohistochemical analysis demonstrated that calprotectin, 4 
TLR4 and NRLP3 proteins were positively stained in the severe infiltrating area in 5 
ANCAGN.  6 
Conclusions. Calprotectin produced by ANCA activated neutrophils may behave as 7 
damage-associated molecular patterns in the sterile inflammation in ANCAGN. These results 8 
indicated that NLRP3 inflammasome may play a characteristic role in the development and 9 
deterioration of TII in ANCAGN. 10 
 11 
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Introduction 1 
In elderly people, myeloperoxidase (MPO) and proteinase-3 (PR3) anti-neutrophil 2 
cytoplasmic antibody (ANCA)-associated crescentic glomerulonephritis (ANCAGN) is a 3 
leading cause of rapidly progressive glomerulonephritis (RPGN), and the principal 4 
histopathological features are glomerular extracapillary proliferation (crescents) and fibrinoid 5 
necrosis1 ),2 ) . Glomerular damage is accompanied by tubulointerstitial damage and generally 6 
accepted that the former causes the latter. We naturally think the grade of crescent formation 7 
should relate with the severity of tubulointerstitial injury (TII), however, several cases reported 8 
in which only TII is noted without any apparent glomerular lesions3) ,4) , and it is also well 9 
known that the severity of TII was not correlated with that of glomerulonephritis in 10 
ANCAGN5 ),6) .  11 
IgA nephropathy (IgAN) is another kidney disease exhibits representative cresentic 12 
glomerulonephritis. IgAN is the most common primary glomerulonephritis worldwide, and 13 
crescent formation is a common histopathological finding, occurring in approximately 20–14 
50% of the patients7)-10). It was clearly showed that crescent lesions are independently 15 
associated with a poor renal outcome in untreated patients and even those treated with 16 
immunosuppressive therapy11) . Most nephrologists realized renal progression correlates more 17 
closely with the severity of tubulointerstitial lesions than with the grade of glomerular 18 
lesions12) . 19 
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The most popular notion for the mechanism of TII associated with 1 
glomerulonephritis is that protein leakage in injured glomeruli into Bowman’s space leads to 2 
excessive protein reabsorption in proximal tubules13) . Adding to this direct damage the 3 
exudates and dying cellular fragmentation into tubular urine resulted from crescent formation 4 
may also act as DAMPs and activate Nod-like receptor family pyrin domain–containing-3 5 
(NLRP3) inflammasome in dendritic cells (DCs) and macrophages harboring in the 6 
tubulointerstitium. As a result TII is developed and progressed. Especially ANCAGN has 7 
distinctive pathological mechanism compared with other glomerulonephritis such as IgAN, 8 
and characteristic activated neutrophils should attack not only glomerular capillaries, but also 9 
interstitial blood vessels. These injuries may activates NLRP3 inflamasome to attack 10 
tubulointerstitium from the start14) .  11 
Calprotectin is a heterodimer complex of two intracellular calcium-binding proteins 12 
S100A8 and S100A9, and expressed by neutrophils, monocytes and early differentiated 13 
macrophages15), 16). It is demonstrated that phagocytes released this complex after their 14 
interaction with activated, inflamed endothelium17). Calprotectin is a Toll-like receptor 4 15 
(TLR-4) ligand, and classed as a DAMP and initiates and perpetuates the immune response. In 16 
the current study we showed that the expression of calprotectin has more close relation to TII 17 
in ANCAGN rather than that in IgAN. The aim of this study is to clarify that calprotectin 18 
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released by ANCA activated neutrophils plays a role as a DAMP for activating NLRP3 1 
inflammasome, and which develops and deteriorate TII.  2 
This study was performed in accordance with the Declaration of Helsinki and was 3 
approved by the ethics committee of Fukuoka University. Written informed consent was 4 
obtained from all patients.    5 
 6 
Materials and Methods 7 
1, Patients 8 
We enrolled 22 patients who were diagnosed with MPO-ANCA-positive 9 
ANCAGN, histologically diagnosed crescentic glomerulonephritis and 25 patients with 10 
crescentic IgAN in the Division of Nephrology and Rheumatology in Fukuoka University 11 
Hospital between January 2015 and December 2018. All ANCAGN patients received kidney 12 
biopsy examinations within 31.2 ± 17.8 days since subjective symptom appeared. While some 13 
IgA patients received biopsy on standby. No steroid or immunosuppressant was prescribed at 14 
the time of kidney biopsy for all enrolled patients. The clinical background data of the patients 15 
are shown in Table 1.  16 
 17 
2, Histological evaluations 18 
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The diagnosis was determined according to the classification of the Japanese Renal 1 
Biopsy Registry based on the classification of glomerular diseases 18). Biopsy specimens were 2 
processed and observed using routine methods, including light microscopy, 3 
immunofluorescence techniques, and electron microscopy. ANCAGN was defined according 4 
to laboratory and histological findings of rapidly progressive glomerulonephritis along with 5 
positive tests for MPO-ANCA.   6 
The severities of cellular crescents formation of glomerulus and cTII were evaluated 7 
in a blind manner by histologic examination with periodic acid-Schiff staining and periodic 8 
acid-methenamine-silver staining. A crescent occupied more than half of the total area by 9 
cellular elements was defined as a cellular crescent, and the percentages of glomeruli showing 10 
cellular crescent for all glomeruli were expressed as an index of the cellular crescent formation 11 
rate (cCFR). Concerning cellular TII (cTII) were evaluated as follows; cTII was an index 12 
defined as the average number of infiltrating cells for five high power field (HPF) areas in 13 
order from having the most infiltrating cells in tubulointerstitium. The observation areas were 14 
selected under eliminating the overlap.  15 
 16 
3, Reverse transcription-polymerase chain reaction (PCR) 17 
Total RNA was extracted from the kidney biopsy specimens collected before 18 
commencing steroid therapy, using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). 19 
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Quantitative cDNA amplification was performed according to the manufacturer’s instructions. 1 
All samples were stored at –20 °C until use. cDNAs of the cytokines were analyzed by 2 
real-time PCR using Power SYBR Green PCR Master Mix (Applied Biosystems Japan, 3 
Tokyo, Japan) or TaqMan Gene Expression Master Mix (Applied Biosystems Japan, Tokyo, 4 
Japan). Sequence-specific amplification was detected with an increased fluorescence signal 5 
during the amplification cycles, using an ABI Prism 7500 sequence detection system (Perkin 6 
Elmer Japan, Yokohama, Japan). To provide a meaningful comparison between different 7 
samples, we calculated the amount of PCR products relative to the amount of β-actin in each 8 
sample. Oligonucleotide primers and probes were designed using the Primer Express program 9 
(Applied Biosystems Japan) or purchased directly. Primers sequences for RT-PCR using 10 
SYBR green chemistry are follows. -actin; 5′ GCA AAG ACC TGT ACG CCA AC 3′ and 5′ 11 
CTA GAA GCA TTT GCG GTG GA 3′, NLRP3; 5’ GAA GAA AGA TTA CCG TAA GAA GTA 12 
CAG AAA 3’ and 5’ CGT TTG TTG AGG CTC ACA CTC T 3’. Purchased Taqman primers were 13 
as follows: Hs01060665-g1 for TLR4, Hs01555410-m1 for interleukin-1IL-1.  14 
 15 
4, Immunohistological analysis 16 
After deparaffinization in xylene and ethanol, and washing in phosphate-buffered 17 
saline (PBS), paraffin-embedded sections were incubated with mouse anti-human TLR-4 18 
antibody (Ab), rabbit anti-human nucleotide-binding domain, leucine-rich–containing family, 19 
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pyrin domain–containing-3 (NLRP3) Ab, and mouse anti-human calprotectin MRP8/14 1 
(Bachem, Bubendorf, Switzerland) at a concentration of 1 g IgG /ml PBS, including 1% 2 
bovine serum albumin or 5% normal goat serum. Monoclonal and polyclonal staining was 3 
performed using anti-mouse or anti-rabbit IgG horseradish peroxidase-labeled polymer (Dako 4 
Cytomation, Inc., Carpinteria, CA, USA). A part of immunofluorescent study was performed 5 
with OPAL-7-plex reagents, imaged at 20X on the Mantra Quantitative Pathology Imaging 6 
System, and analyzed using inForm software (all from Perkin-Elmer, Waltham, MA, USA). 7 
Calprotectin positivity was evaluated as follows. The average number of positive 8 
cells of five glomeruli in order from having the most abundant positive cells was defined as 9 
glomerular calprotectin positive score (GCP score). Similarly, tubulointerstitium calprotectin 10 
positive score (TICP score) was defined for five HPF areas in tubulointerstitium. The 11 
observation areas were selected under eliminating the overlap.       12 
 13 
5, Statistical analysis 14 
Statistical significance of the differences between groups was determined by 15 
Pearson’s rank correlation coefficient. All statistical analyses in this study were performed 16 
using SPSS statistics software version 23. P-values <0.05 were considered to be statistically 17 
significant. 18 
          19 
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Results 1 
1, Histological evaluation of TII   2 
1) Correlation of the severity between glomerular injury (GI) and TII 3 
We evaluated the relationship between GI and TII. Pearson’s correlation coefficient 4 
for IgAN was r=0.400 (P-value 0.047), and the value of cTII was correlated with that of cCFR. 5 
While correlation coefficient for ANCAGN was r=0.336 (P-value 0.068), and correlation was 6 
denied (Fig. 1). This result supported the notion that there is a different mechanism for TII in 7 
ANCAGN from that in IgAN.  8 
 9 
2) Immunohistological analysis for calprotectin  10 
 We evaluated the calprotectin positivity for both ANCAGN (Fig. 2A) and IgAN 11 
(Fig. 2B). Within and around a crescent prominent expression calprotectin-positive cells were 12 
seen, but not within sclerosed glomeruli in both diseases. Abundant calprotectin-positive cells 13 
around a small vessel were apparent in ANCAGN rather than in IgAN (Fig. 2C). GCP scores 14 
in ANCAGN and IgAN were 3.34±5.63 and 3.20±3.90, respectively (P-value 0.523). While 15 
TICP scores in ANCAGN and IgAN were 9.19±9.10 and 2.4±3.53, respectively(P-value 16 
0.015). The correlation coefficients between GCP and TICP scores in ANCAGN and IgAN 17 
were r=0.464 (P-value 0.03) and r=0.541(P-value 0.005), respectively (Fig. 3).  18 
    19 
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2, Role of the inflammasome in TII in ANCAGN 1 
The value of TICP showed a close correlation with cTII (coefficient 0.459, P-value 2 
0.036) (Fig 4A). The expression of TLR4 was correlated with TICP (coefficient 0.459, P-value 3 
0.036) (Fig 4B). The expressions of NLRP3 (coefficient 0.365, P-value 0.095) and IL-1β 4 
(coefficient 0.167, P-value 0.459) were not correlated (data not shown). 5 
While the value of cTII showed the positive correlations with the expression of 6 
TLR4 (coefficient 0.469, P-value 0.028), NLRP3 (coefficient 0.434, P-value 0.044), and IL-1β 7 
(coefficient 0.520, P-value 0.013), respectively (Fig. 5).   8 
Immunohistochemical analysis demonstrated that TLR4 protein was stained some 9 
tubulointerstitial infiltrating cells. Many NLRP3-positive cells were observed in the severe 10 
infiltrating area, and similarly, calprotectin positive cells were scattered in the 11 
tubulointerstitium, but the number of these cells was less than one-fifth that of NLRP3-positive 12 
cells. Almost all of these positive cells were also positive for CD68 expression (data not 13 
shown). Results by Mantra Quantitative Pathology Imaging System showed the distribution of 14 
calprotectin, TLR4, and NLRP3-positive cells. Many NLRP3-positive cells and several 15 
TLR4-positive cells surrounded calprotectin positive area were shown. However, 16 
NLRP3-positive cells were also observed calprotectin negative area such as perivascular 17 
region (Fig. 6).    18 
 19 
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 1 
Discussion 2 
In this study we showed that the correlation between the severity of GI and TII 3 
was not recognized in ANCAGN. In general, glomerulonephritis is associated with 4 
tubulointerstitial lesions to some extent, and it is universally agreed that glomerular damage is 5 
the cause of TII. In fact although the severity of GI and TII were correlated in IgAN, no 6 
significant correlation was recognized in patients with ANCAGN (Fig. 1). These results 7 
indicated that a distinctive mechanism effected on TII in ANCAGN. A marked characteristic 8 
of pathological condition in ANCAGN is that activated neutrophils and monocytes have 9 
important role in pathogenesis. ANCAs have been shown to induce neutrophil extracellular 10 
traps (NETs)17),19) and which are present in kidney biopsies of ANCAGN patients19), 20) . 11 
Although NETs play an important immune defense role showing an antimicrobial 12 
mechanism coexisting with enzyme degranulation and reactive oxygen species production, 13 
they express potential autoantigens and have therefore been implicated in the pathogenesis of 14 
ANCAGN21),22). Actually NETs consist of expelled chromatin loaded with lysozomal and 15 
cytosolic proteases23) , and involve massive danger associated molecular patterns (DAMPs). 16 
In the extracellular space these DAMPs can bind to pattern recognition receptors (PRRs) or 17 
to specialized DAMP receptors to activate the immune system by promoting release of 18 
pro-inflammatory mediators24). The immune cells that participate in these processes are 19 
mainly DCs and macrophages harboring in the intertubular interstitium. They survey against 20 
injury and infection and contribute to organ homeostasis but may also promote the 21 
progression of CKD25) .  22 
Calprotectin is a heterodimer complex of S100A8 and S100A9, and it has been 23 
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widely reported that fecal calprotectin (FC) levels reflect regional inflammation of the gastrointestinal 1 
tract, and that the FC level was useful as a reliable surrogate marker of endoscopic and histologic 2 
activity in ulcerative colitis26), 27), 28).  In the patient with ANCA-associated vasculitis it was 3 
demonstrated that calprotectin is up-regulated and represents a marker of cellular immune 4 
activation and disease activity29). It was also shown that elevated serum levels of calprotectin may 5 
be used as an indicator of severe disease and cardiovascular disease (CVD) in systemic lupus 6 
erythematosus (SLE)30), and demonstrated platelet calprotectin levels were increased in SLE 7 
patients, particularly in those with CVD31). The fact that calprotectin was extracellulary 8 
released during NETosis21), 23) deserves attention, and this reaction remind us the existence of 9 
specific mechanism for TII in ANCAGN. In this study the expressions of calprotectin in the 10 
renal biopsies of patients with ANCAGN and IgAN were examined. The conspicuous 11 
expression of calprotectin was recognized within active crescents and in areas of focal 12 
necrosis, but was absent in sclerotic or normal glomeruli (Fig. 2). TICP and GCP scores were 13 
indexes of calprotectin positive cells in TII and glomerulus, respectively, and these were 14 
correlated in both diseases. But calprotectin-positive cells in cellular infiltration area in 15 
ANCAGN were much abundant compared with that in IgAN (Fig. 3). The values of TICP 16 
scores reflected the severities of cTII, and the mRNA expression level of TLR4, which is a 17 
receptor of calprotectin, was also correlated with the TICP scores (Fig. 4). However, the 18 
mRNA expression levels of NLRP3 and IL-1 were not correlated with TICP scores (Fig. 5). 19 
On the other hand increase of the values of cTII was incorporate with the gain of message for 20 
TLR4, NLRP3 and IL-1 (Fig. 6). The fact that the message of NLRP3 and IL-1 correlated 21 
with cTII, but not with TICP may reflect the following context; It is thought that many 22 
DAMPs other than calprotectin also may be concerned with this reaction. In addition other 23 
mechanisms than sterile inflammation should play some role in TII. The production of IL-1 24 
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is limited to interstitial monocytic phagocytes/DCs that having the components of the 1 
NLRP3 inflammasome inside the kidney32), 33), and this sterile inflammation with NLRP3 2 
inflammasome mechanism with calprotectin and many other DAMPs may work in TII in 3 
ANCAGN. In immunohistologic study some tubulointerstitial infiltrating macrophages 4 
showed positive staining for TLR4 and NLRP3. Apparently the areas where calprotectin 5 
deposits were surrounded with NLRP3-positive cells or TLR4-positive cells were observed, 6 
but the region of accumulation of NLRP3-positive cells without calprotectin deposits also 7 
recognized (Fig. 6). This distribution may indicate that not only calprotectin, a varieties of 8 
DAMPs contribute to innate immunological response through NLRP3 inflammasome. 9 
From a therapeutic standpoint, developing therapeutic method to regulate the 10 
NLRP3 inflammasome is important to treat TII in ANCAGN. Colchicine is a tubulin 11 
polymerization inhibitor, and consistently disrupts the assembly of the NLRP3 12 
inflammasome34). Although colchicine is a powerful medication for gout to suppress 13 
inflammasome activity, it is toxic for cells and tissues and causes several adverse effects35). 14 
Therefore, colchicine is not appropriate for the treatment of chronic inflammatory diseases. 15 
Instead it was demonstrated that resveratrol, which is a naturally occurring compound 16 
produced by many types36), prevents the accumulation of acetylated α-tubulin, suppresses 17 
NLRP3-inflammasome assembly, and subsequent inflammatory responses37). It was also 18 
reported that MCC950 is a novel, selective small-molecule NLRP3-inflammasome inhibitor with 19 
powerful in vitro and in vivo inhibitory effects, enabling clinically relevant testing in large animal 20 
models38), 39). On the other hand, neutralizing IL-1β may also represent a rational strategy for TII 21 
in ANCAGN. Anakinra, a recombinant IL-1β receptor antagonist has been successfully used 22 
in the treatment of type 2 diabetes, asbestosis, and other conditions in the United States40). It 23 
was recently reported that Canakinumab is a human anti- IL-1β monoclonal antibody and 24 
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reduced major adverse cardiovascular event rates among high-risk atherosclerosis patients with 1 
CKD41). The prognosis of ANCAGN mainly depends on improvement of GI and TII, and 2 
thus targeting inflammasome or IL-1β appears to be a promising strategy to ameliorate TII 3 
and prevent interstitial fibrosis. 4 
The present study had several limitations. Firstly, the study was performed at a single 5 
center, and histological severity grades and score were evaluated using self-defined definition. 6 
Secondary we had to match some condition to compare between ANCAGN and IgAN, which are 7 
completely different diseases in patient population and clinical stage, thus this study involved a 8 
limited number of patients, particularly those with crescentic IgAN. Finally we could not present 9 
inflammasome activity anymore than the expression of mRNA of inflamasome-related molecules. 10 
In summary, calprotectin is a useful surrogate marker for ulcerative colitis, and its 11 
role for DAMPs is watched with interest. In ANCAGN calprotectin produced activated 12 
neutrophils may behave as a DAMPs to activate NLRP3 inflammasome in the DCs and 13 
macrophages within the tubulointerstitium. These reactions induce the release IL-1β, and 14 
which may result in development and deterioration of TII. NLRP3-inflammasome inhibitor or 15 
neutralizing IL-1β may be excellent strategies to suspend the progress of TII and improve the 16 
prognosis of CKD resulting from ANCAGN.    17 
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Legends for Figures 3 
 Fig. 1： The correlation between GI and TII in IgAN and ANCAGN.  4 
For severity quantitation of GI and TII, cCFR and cTII are evaluated from the 5 
histological findings of renal biopsy specimen of each case and they are plotted to examine the 6 
correlation between them.   7 
 8 
Fig. 2: Light microscopy of the kidney biopsy.  9 
Immunohistochemical study revealed calprotectin positive cells are seen within 10 
active crescents and in areas of focal necrosis. (A) ANCAGN, (B) IgAN, (C) around a small 11 
vessel in ANCAGN. 12 
 13 
Fig. 3: The correlation between GCP and TICP scores in IgAN and ANCAGN. 14 
GCP and TICP scores are evaluated from the immunohistological findings of renal biopsy 15 
specimen of each case and they are plotted to examine the correlation between them.   16 
 17 
Fig. 4: The correlation between cTII and TICP scores, and mRNA expression 18 
level of TLR4 and TICP score in ANCAGN.  19 
25 
 
 1 
Fig. 5: The correlation of cTII with mRNA expression level of TLR4, NLRP3, 2 
and IL-1β in ANCAGN. 3 
A. The correlation between cTII and mRNA expression level of TLR4. 4 
B. The correlation between cTII and mRNA expression level of NLRP3. 5 
C. The correlation between cTII and mRNA expression level of IL-1. 6 
 7 
Fig. 6: Immnofluoresecnt study by Mantra Quantitative Pathology Imaging 8 
System shows the distribution of infiltrating cells.  9 
Calprotectin deposits (cyan), NLRP3-positive cells (magenta), TLR4-positive 10 
cells (green), and nucleus (blue) are shown in the tubulointerstitium.   11 
 12 
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 14 
ANCA(n=22) IgAN(n=25)
Age 65.6±15.1 38.5±14.6
Sex Male: 12 Female: 10 Male: 10 Female: 15
WBC (/μL) 12,531 ± 19,290 7,246 ± 3,194
TP (g/dl) 6.66 ± 0.81 5.81 ± 2.22
Alb (g/dl) 2.59 ± 0.80 4.85 ± 11.3
BUN (mg/dl) 34.4 ± 19.5 14.8 ± 7.41
Cr (mg/dl) 9.98 ± 4.12 0.91 ± 0.57
eGFR (ml/min/1.73m2) 28.78 ± 26.5 57.32 ± 31.68
CRP (mg/dl) 8.00 ± 6.71 0.21 ± 0.45
MPO-ANCA (U/ml) 189.3 ± 187.6 not examined
IgG (mg/dl) 1,547 ± 601 916 ± 475
U-Protein (g/day) 1.34± 1.30 1.67 ± 1.65
U-β2MG (µg/l) 14,414 ± 18,404 1,250± 3,234
U-NAG (IU/l) 19.3±13.0 14.6 ± 18.3
Table 1. Patients characteristics at the time of kidney biopsy   
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